What's new

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 7, Status: Authorised

May 15, 2025 - 10:02
 0
Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 7, Status: Authorised
Read More

Tags:

Previous Article

Opinion: Ensuring most-favored nation drug pricing doesn’t sicken us

Next Article

Human medicines European public assessment report (EPAR): Winlevi, clascoterone,...

Related Posts

Artificial intelligence

Artificial intelligence

May 7, 2025  0

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

May 15, 2025  0

EMEA-003130-PIP02-23

EMEA-003130-PIP02-23

May 12, 2025  0